Mga Batayang Estadistika
| LEI | 529900AKIOSC15Y63R18 |
| CIK | 1498403 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioLineRx Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2025 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2025 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive income (loss) F-2 Condensed consolidated i |
|
| August 14, 2025 |
Exhibit 1 For Immediate Release BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 - - Provides updated and extended cash runway guidance into H1 2027 - - Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel, August 14, 2025 – BioLineRx Ltd. |
|
| August 14, 2025 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 31, 2025 (the “Annual Report”). |
|
| August 14, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| July 25, 2025 |
BioLineRx Ltd. Up to $4,870,000 of American Depositary Shares Representing Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024) BioLineRx Ltd. Up to $4,870,000 of American Depositary Shares Representing Ordinary Shares We are filing this prospectus supplement to amend the prospectus, dated January 5, 2024, filed as a part of our registration statement on Form F-3 (File No. 333-276323), or the Registratio |
|
| June 30, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check m |
|
| May 30, 2025 |
Exhibit 1 For Immediate Release BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting – 4 of 11 PDAC patients in the pilot phase remained progression free at over one year – – Poster presentation on Saturday, May 31st – TEL AVIV, Israel, May 30, 2025 – BioLineRx Ltd. |
|
| May 30, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 27, 2025 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2025 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2025 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 2 Condensed consolidated interim statements of comprehensive income (loss) 3 Condensed consolidated int |
|
| May 27, 2025 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 31, 2025 (the “Annual Report”). |
|
| May 27, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 27, 2025 |
Exhibit 1 For Immediate Release BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update - Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Management to host conference call today, May 27th, at 8:30 am EDT - TEL AVIV, Israel, May 27, 2025 – BioLineRx Ltd. |
|
| May 23, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 23, 2025 |
Annual General Meeting of Shareholders Exhibit 99.3 BNY: PO BOX 505006, Louisville, KY 40233-5006 Your vote matters! Have your ballot ready and please use one of the methods below for easy voting: Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. BioLineRx, Ltd. Mail: Annual General Meeting of Shareholders • Mark, sign and date your Proxy Car |
|
| May 23, 2025 |
BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on June 29, 2025 BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on June 29, 2025 Notice is hereby given that the Annual General Meeting of the shareholders (the “Meeting”) of BioLineRx Ltd. (the “Company”) will be held at the offices of the Company at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel, on Sunday, June 29, 2025, at 3:00 p.m. (Israel time), for the follo |
|
| May 23, 2025 |
Exhibit 99.2 BIOLINERX LTD. For the Annual General Meeting of Shareholders to be held on June 29, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of BioLineRx Ltd. (the “Company”) hereby appoints Mali Zeevi and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, |
|
| April 11, 2025 |
Up to $4,800,000 of American Depositary Shares Representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 5, 2024) Up to $4,800,000 of American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements certain information in the prospectus, dated January 5, 2024, or the ATM Prospectus, filed with the Securities and Exchange Commission as part of our reg |
|
| March 31, 2025 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 31, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-176419, 333-183976, 333-201326, 333-208865, 333-269334 ,333-276325 and 333-284059) and Form F-3 (Nos. 333-239485, 333-229021 and 333-276323) of BioLineRx Ltd. of our report dated March 31, 2025 relating to the financial state |
|
| March 31, 2025 |
Exhibit 1 For Immediate Release BioLineRx Reports 2024 Financial Results and Provides Corporate Update - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. |
|
| March 31, 2025 |
PLACEMENT AGENT WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Exhibit 4.40 PLACEMENT AGENT WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of ADSs: Initial Exercise Date: January 7, 2025 THIS PLACEMENT AGENT WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s |
|
| March 31, 2025 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 31, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| March 31, 2025 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 31, 2025 |
Title: Securities Trades by BioLineRx Personnel Exhibit 11.1 Title: Securities Trades by BioLineRx Personnel 1. PURPOSE BioLineRx Ltd. (the “Company”) management wants to ensure that the Company and its employees are protected from legal liability with respect to the trading of the Company’s securities. These procedures reflect management policy and the implementation thereof. 2. SCOPE The Policy applies to all Company personnel, including dire |
|
| March 31, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2024, BioLineRx Ltd. had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or Exchange Act: our ordinary shares and American Depositary Shares, or ADSs. References herein to “we,” “us,” “our” and the “Company” refer to BioLineRx Ltd. and i |
|
| March 31, 2025 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| March 31, 2025 |
Exhibit 1.1 BioLineRx Ltd. Articles of Association of a Public Company In accordance with The Companies Law, 5759-1999 As of October 1, 2024 BioLineRx Ltd. 1. Name of Company The name of the Company is BioLineRx Ltd. 2. Goals of the Company The goal of the Company is to engage in any lawful business. 3. Interpretation 3.1 Any statement in the singular shall also include the plural and vice versa; |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| January 21, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| January 21, 2025 |
Exhibit 1 BioLineRx Issues Letter to Shareholders - Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel - January 21, 2025 – BioLineRx Ltd. |
|
| January 17, 2025 |
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares Exhibit 1 For Immediate Release BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares Tel Aviv, Israel, January 17, 2025 – BioLineRx Ltd. |
|
| January 17, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| January 10, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 7, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| January 7, 2025 |
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Exhibit 10.3 EXHIBIT A-2 WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of ADSs: Initial Exercise Date: January 7, 2025 THIS WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any tim |
|
| January 7, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2025, between BioLineRx Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms |
|
| January 7, 2025 |
424B5 1 zk2532521.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024) 34,332,122 American Depositary Shares Representing 514,981,830 Ordinary Shares Pre-Funded Warrants to Purchase 15,667,878 American Depositary Shares Representing 235,018,170 Ordinary Shares Warrants to Purchase 50,000,000 American Depositary Shares Re |
|
| January 7, 2025 |
PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Exhibit 10.2 PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of ADSs: Initial Exercise Date: January 7, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| January 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| January 6, 2025 |
BioLineRx Announces $10 Million Registered Direct Offering Exhibit 1 BioLineRx Announces $10 Million Registered Direct Offering TEL AVIV, Israel, January 6, 2025 - BioLineRx Ltd. |
|
| December 27, 2024 |
As filed with the Securities and Exchange Commission on December 27, 2024. As filed with the Securities and Exchange Commission on December 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLINERX LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel Not Applicable (State or other jurisdiction of incorporation or organization) (I |
|
| December 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioLineRx Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value NIS |
|
| December 27, 2024 |
Exhibit 4.1 BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan (as extended and approved effective as of May 22, 2024) (In compliance with Amendment No. 132 of the Israeli Tax Ordinance, 2002) 1. Name This plan, as amended from time to time, shall be known as the “BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan” (the “Plan”). 2. Purpose The purpose and intent of the Plan i |
|
| November 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 25, 2024 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2024 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2024 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive loss F-2 Condensed consolidated |
|
| November 25, 2024 |
Exhibit 1 For Immediate Release BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value - Executed license agreement with Ayrmid Ltd. |
|
| November 25, 2024 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F/A filed on March 26, 2024 (the “Annual Report”). |
|
| November 21, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 21, 2024 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 20, 2024, by and between BioLineRx Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, |
|
| November 21, 2024 |
Exhibit 10.1 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed License Agreement This License Agreement (this “Agreement”) is entered into as of November 20, 2024 (the “License Effective Date”), |
|
| November 21, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024) 4,121,493 American Depositary Shares Representing 61,822,395 Ordinary Shares Pre-Funded Warrants to Purchase 12,349,956 American Depositary Shares Representing 185,249,340 Ordinary Shares Warrants to Purchase 8,235,724 American Depositary Shares Representing 123,535,860 Ordinary |
|
| November 21, 2024 |
PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Exhibit 10.4 PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of ADSs: Initial Exercise Date: November 21, 2024 Issue Date: November 21, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the co |
|
| November 21, 2024 |
Exhibit 99.1 BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. – BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and comm |
|
| November 21, 2024 |
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Exhibit 10.5 WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of ADSs: Initial Exercise Date: November 21, 2024 Issue Date: November 21, 2024 THIS WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this "Warrant") certifies that, for value received, or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s |
|
| November 21, 2024 |
FIRST AMENDMENT (this “Amendment”) Dated November 14, 2024 to: Exhibit 10.2 FIRST AMENDMENT (this “Amendment”) Dated November 14, 2024 to: that certain AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO US$ 40,000,000 dated as of September 14, 2022 (the “Loan Agreement”) between KREOS CAPITAL VII AGGREGATOR SCSP, a special limited partnership incorporated in Luxembourg under registered number B264706 whose registered office is at 1 Boulevard de la Foire, |
|
| November 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 5, 2024 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle - - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass. |
|
| November 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| October 16, 2024 |
Exhibit 1 BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide – Allowance strengthens company’s intellectual property estate and extends motixafortide patent protection in the U. |
|
| October 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| October 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| August 19, 2024 |
Annual General Meeting of Shareholders of BIOLINERX LTD. Exhibit 99.3 Annual General Meeting of Shareholders of BIOLINERX LTD. Annual General Meeting of Shareholders of BIOLINERX LTD. to be held on October 1, 2024 For Holders as of August 26, 2024 Date: October 1, 2024 See Voting Instruction On Reverse Side. Please make your marks like this: ☒ Use dark black pencil or pen only For Against Abstain 1. TO APPROVE the re-election of the following persons as |
|
| August 19, 2024 |
Exhibit 99.2 BIOLINERX LTD. For the Annual General Meeting of Shareholders to be held on October 1, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of BioLineRx Ltd. (the “Company”) hereby appoints Netanel Derovan and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substit |
|
| August 19, 2024 |
BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 1, 2024 Exhibit 99.1 BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 1, 2024 Notice is hereby given that the Annual General Meeting of the shareholders (the “Meeting”) of BioLineRx Ltd. (the “Company”) will be held at the offices of the Company at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel, on Tuesday, October 1, 2024, at 3:00 p.m. (Israel ti |
|
| August 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| August 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| August 15, 2024 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2024 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2024 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive income (loss) F-2 Condensed consolidated i |
|
| August 15, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA |
|
| August 15, 2024 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F/A filed on March 26, 2024 (the “Annual Report”). |
|
| June 18, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check m |
|
| May 30, 2024 |
Exhibit 1 BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children’s Research Hospital, Inc. and two |
|
| May 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 28, 2024 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F/A filed on March 26, 2024 (the “Annual Report”). |
|
| May 28, 2024 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2024 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2024 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 2 Condensed consolidated interim statements of comprehensive loss 3 Condensed consolidated interim stat |
|
| May 28, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 28, 2024 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~3 |
|
| May 24, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 24, 2024 |
Exhibit 1 BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated - - 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control - - Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois - TEL AVIV, Israel, May 24, 2024– BioLineRx Ltd. |
|
| May 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 17, 2024 |
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 1 BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification TEL AVIV, Israel, May 17, 2024– BioLineRx Ltd. |
|
| May 6, 2024 |
Exhibit 1 BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 -Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia TEL AVIV, Israel, May 6, 2024– BioLineRx Ltd. |
|
| May 6, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| April 17, 2024 |
Exhibit 1 BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting TEL AVIV, Israel, April 17, 2024– BioLineRx Ltd. |
|
| April 17, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| April 10, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| April 10, 2024 |
Exhibit 1 BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program - TEL AVIV, Israel, April 10, 2024– BioLineRx Ltd. |
|
| April 1, 2024 |
BioLineRx Announces $6 Million Registered Direct Offering Exhibit 99.1 BioLineRx Announces $6 Million Registered Direct Offering TEL AVIV, Israel, April 1, 2024 – BioLineRx Ltd. (NASDAQ/TASE: BLRX) (“BioLineRx” or the “Company”), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance an |
|
| April 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276323 PROSPECTUS SUPPLEMENT (To prospectus dated January 5, 2024) 7,500,000 American Depositary Shares Representing 112,500,000 Ordinary Shares Warrants to Purchase 7,500,000 American Depositary Shares Representing 112,500,000 Ordinary Shares We are offering 7,500,000 American Depositary Shares, or ADSs, representing 112,500,000 of our ordinar |
|
| April 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| April 1, 2024 |
BIOLINERX LTD. Warrant To Purchase American Depositary Shares Exhibit 10.2 BIOLINERX LTD. Warrant To Purchase American Depositary Shares Warrant No.: Number of American Depositary Shares: Date of Issuance: April 1, 2024 (“Issuance Date”) BIOLINERX LTD., an Israeli company (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its perm |
|
| April 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2024, between BioLineRx Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in |
|
| March 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| March 26, 2024 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 26, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 26, 2024 |
Exhibit 97.1 BioLineRx Ltd. Executive Officer Clawback Policy Approved by the Compensation Committee of the Board of Directors on November, 2023 (the “Adoption Date”) I. Purpose This Executive Officer “Clawback” Policy (or “Policy”) describes the circumstances under which Covered Persons, as defined herein, of BioLineRx Ltd. and any of its direct or indirect subsidiaries (the “Company”) will be re |
|
| March 26, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-176419, 333-183976, 333-201326, 333-208865, 333-269334 and 333-276325) and Form F-3 (No. 333,239485, 333-229021 and 333-276323) of BioLineRx Ltd. of our report dated March 26, 2024 relating to the financial statements and the |
|
| March 26, 2024 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 26, 2024 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| March 26, 2024 |
Exhibit 2.1 BioLineRx Ltd. Articles of Association of a Public Company In accordance with The Companies Law, 5759-1999 As of August 7, 2023 BioLineRx Ltd. 1. Name of Company The name of the Company is BioLineRx Ltd. 2. Goals of the Company The goal of the Company is to engage in any lawful business. 3. Interpretation 3.1 Any statement in the singular shall also include the plural and vice versa; a |
|
| March 26, 2024 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates - Reported significant commercial progress for APHEXDA® - secured payer coverage representing ~95% of covered lives in the U. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 26, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 26, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 26, 2024 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| March 26, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 26, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, BioLineRx Ltd. had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or Exchange Act: our ordinary shares and our American Depositary Shares, or ADSs. References herein to “we,” “us,” “our” and the “Company” refer to BioLineRx Ltd. a |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O |
|
| March 26, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-176419, 333-183976, 333-201326, 333-208865, 333-269334 and 333-276325) and Form F-3 (No. 333,239485, 333-229021 and 333-276323) of BioLineRx Ltd. of our report dated March 26, 2024 relating to the financial statements and the |
|
| March 4, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| March 4, 2024 |
Exhibit 1 BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U. |
|
| February 28, 2024 |
Exhibit 1 BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) - Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD, PhD, of Columbia University to present encore pilot phase data at the Immuno-Oncology (IO) 360° Summit on February 29 - TEL AVIV, Israel, February 28, 2024– BioLineRx Ltd. |
|
| February 28, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| February 16, 2024 |
Exhibit 1 BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® - Results include pharmacokinetic and pharmacodynamic data, and post-hoc subgroup analyses of the Phase 3 GENESIS trial - - Presentations on Thursday, February 22, 2024 in San Antonio, Texas - TEL AVIV, Israel, February 16, 2024– BioLineRx Ltd. |
|
| February 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| December 29, 2023 |
As filed with the Securities and Exchange Commission on December 29, 2023. As filed with the Securities and Exchange Commission on December 29, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLINERX LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel Not Applicable (State or other jurisdiction of incorporation or organization) (I |
|
| December 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) BioLineRx Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Re |
|
| December 29, 2023 |
As filed with the Securities and Exchange Commission on December 29, 2023 As filed with the Securities and Exchange Commission on December 29, 2023 Registration No. |
|
| December 29, 2023 |
Calculation of Filing Fee Tables Form S-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioLineRX Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value NIS |
|
| December 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| December 21, 2023 |
Exhibit 1 BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel, December 21, 2023– BioLineRx Ltd. |
|
| December 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 20, 2023 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 22, 2023 (the “Annual Report”). |
|
| November 20, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 20, 2023 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2023 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2023 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive loss F-2 Condensed consolidated |
|
| November 20, 2023 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma - - Closed Exclusive License Agreement for Motixafo |
|
| October 26, 2023 |
BLRX / Bioline Rx Ltd - ADR / Hong Seng Technology Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BioLineRx Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.10 per share (Title of Class of Securities) Jia Liu/ Bingfeng Zhang 7#, No.37 Chao Qian Road Changping Tech. Zone Beijing, P.R. China 86-010-80123864/ 86-010-80120767 (Name, Address and Tele |
|
| October 26, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) jointly |
|
| October 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| October 12, 2023 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment - License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential commercial milestones, and tiered double- digit royalties on sales - - Gloria Bioscience |
|
| September 28, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| September 28, 2023 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) - 6 of 11 Patients in the Pilot Phase Experienced a Partial Response, with 4 Confirmed; One Patient Experienced Resolution of the Hepatic Metastatic Lesion - - Data Presented at AACR Special Conference on Pancreatic Cancer - - Multi-Center, Randomized Phase 2 Study Currently Enrolling - TEL AVIV, Israel, September 28, 2023 – BioLineRx Ltd. |
|
| September 11, 2023 |
Exhibit 1 BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma - APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U. |
|
| September 11, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| August 30, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| August 30, 2023 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2023 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2023 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive loss F-2 Condensed consolidated interim st |
|
| August 30, 2023 |
Exhibit 10.1 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed License Agreement This License Agreement is entered into as of 27 August, 2023 (the “Execution Date”), by and among BioLineRx, Ltd., |
|
| August 30, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| August 30, 2023 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 22, 2023 (the “Annual Report”). |
|
| August 30, 2023 |
Exhibit 1 FOR IMMEDIATE RELEASE BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates - On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) - - Signed Exclusive License Agreement to Motixafortide in Asia Region with Concurrent Equity Investment - - Announced Initiation of Investigator-Initiated Randomized Phase 2 Combination Trial with Motixafortide in First Line PDAC in Collaboration with Columbia University - - Management to host conference call today, August 30, at 10:00 am EDT - TEL AVIV, Israel, August 30, 2023 – BioLineRx Ltd. |
|
| August 30, 2023 |
Exhibit 10.2 EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISK, HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 27, 2023 |
|
| August 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| July 17, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check m |
|
| July 17, 2023 |
Exhibit 1 BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide TEL AVIV, Israel, July 17, 2023 – BioLineRx Ltd. |
|
| June 23, 2023 |
BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on August 7, 2023 Exhibit 1 BIOLINERX LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on August 7, 2023 Notice is hereby given that the Annual General Meeting of the shareholders (the “Meeting”) of BioLineRx Ltd. (the “Company”) will be held at the offices of the Company at Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel, on August 7, 2023, at 3:00 p.m. (Israel time), for the f |
|
| June 23, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check m |
|
| June 23, 2023 |
Exhibit 3 BIOLINERX LTD. Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 p.m. EST on August 2, 2023) The undersigned shareholder of BioLineRx Ltd. (the “Company”) hereby appoints Mali Ze’evi and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as desig |
|
| June 23, 2023 |
Exhibit 2 BIOLINERX LTD. For the Annual General Meeting of Shareholders to be held on August 7, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of BioLineRx Ltd. (the “Company”) hereby appoints Mali Zeevi and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to |
|
| May 24, 2023 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2023 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2023 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 2 Condensed consolidated interim statements of comprehensive loss 3 Condensed consolidated interim stat |
|
| May 24, 2023 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 24, 2023 |
Exhibit 1 For Immediate Release BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates - On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) - - Rapidly Advancing U. |
|
| May 24, 2023 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 22, 2023 (the “Annual Report”). |
|
| April 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 6-K 1 zk2329582.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Off |
|
| April 25, 2023 |
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 1 For Immediate Release BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement TEL AVIV, Israel, April 25, 2023 – (PRNewswire) – BioLineRx Ltd. |
|
| April 17, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| April 17, 2023 |
Exhibit 1 BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma - GENESIS trial achieved statistical significance (p<0. |
|
| March 22, 2023 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 22, 2023 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| March 22, 2023 |
Exhibit 1 For Immediate Release BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates - Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M. |
|
| March 22, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-176419, 333-183976, 333-201326, 333-208865 and 333-269334) and Form F-3 (No. 333-222332, 333-251857 and 333-229021) of BioLineRx Ltd. of our report dated March 22, 2023 relating to the financial statements and the effectivenes |
|
| March 22, 2023 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| March 22, 2023 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 6, 2023 |
Exhibit 1 For Immediate Release BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas - TEL AVIV, Israel, March 6, 2023 – (PRNewswire) – BioLineRx Ltd. |
|
| March 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| January 20, 2023 |
Calculation of Filing Fee Tables Form S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) BioLineRx Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value NIS 0.10 per sh |
|
| January 20, 2023 |
As filed with the Securities and Exchange Commission on January 20, 2023. As filed with the Securities and Exchange Commission on January 20, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOLINERX LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel Not Applicable (State or other jurisdiction of incorporation or organization) (I. |
|
| January 4, 2023 |
6-K 1 zk2328939.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive O |
|
| January 4, 2023 |
Exhibit 1 For Immediate Release BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer - Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities - TEL AVIV, Israel, January 4, 2023 – (PRNewswire) – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology |
|
| December 20, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors - Study Met Primary Endpoint for Safety and Tolerability - - First-in-Human, Single-Agent Study Demonstrated Immune Activity Across Multiple Biomarkers - - Company to Seek Publication of Complete Data Analysis in 2023 - TEL AVIV, Israel, December 20, 2022 – (PRNewswire) – BioLineRx Ltd. |
|
| December 20, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 15, 2022 |
Exhibit 1 For Immediate Release BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates - Announced FDA acceptance of APHEXDA? (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023 - - Introduced plan to commercialize APHEXDA? independently in the U. |
|
| November 15, 2022 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2022 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2022 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 1 Condensed consolidated interim statements of comprehensive loss 2 Condensed consolidated inte |
|
| November 15, 2022 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and ?nancial condition and prospects in conjunction with the ?nancial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 16, 2022, as amended on September 9, 2022 (the ?Annual Report?). |
|
| November 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 10, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization - PDUFA target action date set for September 9, 2023 - - NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance - - Company advancing preparations for robust comm |
|
| November 4, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 4, 2022 |
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 1 For Immediate Release BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification TEL AVIV, Israel, November 4, 2022 ? (PRNewswire) ? BioLineRx Ltd. |
|
| November 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 3, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting - Full data from pharmacoeconomic study will be presented demonstrating significant cost benefits from using motixafortide in combinat |
|
| September 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| September 27, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Company to accelerate availability to patients and maximize value through independent commercialization to well-defined U.S. transplant center community - - Veteran product launch leader Holly May named President, BioLineRx USA - - Company introduces APHEXDA as Mo |
|
| September 21, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| September 21, 2022 |
Form of Warrant to be issued by BioLineRx Ltd. on September 21, 2022 Exhibit 10.2 WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of American Depositary Shares: [ Initial Exercise Date: [ Issue Date: [ THIS WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth |
|
| September 21, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 18, 2022, between BioLineRx Ltd., a company organized under the laws of Israel (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the ter |
|
| September 21, 2022 |
Form of Placement Agent Warrant to be issued by BioLineRx Ltd. on September 21, 2022 Exhibit 10.3 PLACEMENT AGENT WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD. Number of American Depositary Shares: [ Initial Exercise Date: September 21, 2022 Issue Date: September 21, 2022 THIS PLACEMENT AGENT WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to th |
|
| September 20, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-251857 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 11, 2021) 13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares Warrants to Purchase 13,636,365 American Depositary Shares Representing 204,545,475 Ordinary Shares Placement Agent Warrants to Purchase 681,818 American Depositary Shares Representing 10,227,270 Ord |
|
| September 19, 2022 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2228483.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive |
|
| September 19, 2022 |
BioLineRx Announces $15 Million Registered Direct Offering EX-99 2 exhibit1.htm PRESS RELEASE Exhibit 1 BioLineRx Announces $15 Million Registered Direct Offering Tel Aviv, Israel, September 19, 2022 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct of |
|
| September 15, 2022 |
Exhibit 2 For Immediate Release BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital - Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved - Tel Aviv, Israel, September 15, 2022 ? BioLineRx Ltd. |
|
| September 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| September 15, 2022 |
AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO US$ 40,000,000 Dated __________, 2022 EX-99 2 exhibit1.htm AGREEMENT FOR THE PROVISION OF LOAN FACILITY OF UP TO US$ 40,000,000 BETWEEN THE COMPANY AND KREOS CAPITAL VII AGGREGATOR SCSP Exhibit 1 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE THEY BOTH ARE NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF P |
|
| September 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by ch |
|
| September 12, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study - - Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U. |
|
| September 9, 2022 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F/A of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| September 9, 2022 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F/A of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| September 9, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-176419, 333-183976, 333-201326 and 333-208865) and Form F-3 (333-239485, 333-251857 and 333-229021) of BioLineRx Ltd. of our report dated March 15, 2022 relating to the financial statements and the effectiveness of internal co |
|
| September 9, 2022 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F/A of the Company for the year ended December 31, |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 20-F/A 1 zk2228441.htm 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PUR |
|
| September 9, 2022 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F/A of the Company for the year ended December 31, |
|
| August 16, 2022 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive loss F-2 Condensed consolidated interim st |
|
| August 16, 2022 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and ?nancial condition and prospects in conjunction with the ?nancial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 16, 2022 (the ?Annual Report?). |
|
| August 16, 2022 |
Exhibit 99.1 For Immediate Release BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks - - Announced appointment of commercial strategy and operations veteran Holly May as U.S.-based Chief Commercial |
|
| August 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| July 5, 2022 |
6-K 1 zk2228089.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offi |
|
| June 28, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) - GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide in all indications - -Collaboration based on positive final results from Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with anti-PD-1 and chemotherapy as second-line metastatic PDAC therapy - Tel Aviv, Israel, June 28, 2022 ? BioLineRx Ltd. |
|
| June 28, 2022 |
6-K 1 zk2228056.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offi |
|
| June 16, 2022 |
EX-99 2 exhibit1.htm BIOLINERX ANNOUNCES APPOINTMENT OF COMMERCIAL STRATEGY AND OPERATIONS VETERAN HOLLY W. MAY AS CHIEF COMMERCIAL OFFICER. For Immediate Release BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer - Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch read |
|
| June 16, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by check m |
|
| May 27, 2022 |
(Continued and to be marked, dated and signed, on the other side) Exhibit 3 Annual General Meeting of Shareholders of BIOLINERX LTD. Date: July 3, 2022 See Voting Instruction On Reverse Side. Please make your marks like this: ? Use dark black pencil or pen only For Against Abstain 1. TO APPROVE the re-election of the following nominees to serve as directors of the Company for the coming year until the next annual general meeting of the Company?s shareholders or |
|
| May 27, 2022 |
Exhibit 2 BIOLINERX LTD. For the Annual General Meeting of Shareholders to be held on July 3, 2022 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of BioLineRx Ltd. (the ?Company?) hereby appoints Mali Zeevi and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to v |
|
| May 27, 2022 |
BIOLINERX LTD. NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS July 3, 2022 Exhibit 1 BIOLINERX LTD. NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS ON July 3, 2022 Notice is hereby given that the Annual General Meeting of the shareholders (the ?Meeting?) of BioLineRx Ltd. (the ?Company?) will be held at the offices of the Company at Modi?in Technology Park, 2 HaMa?ayan Street, Modi?in 7177871, Israel, on July 3, 2022 at 3:00 p.m. (Israel), for the following purpose |
|
| May 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 11, 2022 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2022 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2022 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 1 Condensed consolidated interim statements of comprehensive loss 2 Condensed consolidated interim stat |
|
| May 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by check ma |
|
| May 11, 2022 |
OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and ?nancial condition and prospects in conjunction with the ?nancial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 16, 2022 (the ?Annual Report?). |
|
| May 11, 2022 |
Exhibit 1 For Immediate Release BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update - On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance - - Progressing critical Motixafortide pre-launch activities while maintaining full optionality on commercialization strategies - - Cash and cash equivalents at March 31, 2022 of $50. |
|
| March 16, 2022 |
6-K 1 zk2227490.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Off |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 16, 2022 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Philip A. Serlin, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstan |
|
| March 16, 2022 |
Amendment to the Compensation Policy for Executives and Directors Exhibit 4.16 [final paragraph Section 3.4] The Company is authorized to purchase insurance policies (including run-off policies) to cover the liability of directors and Executives that are currently in office and that shall be in office from time to time, including directors and Executives that may have a controlling interest in the Company (if such becomes applicable in the future), within the fo |
|
| March 16, 2022 |
Exhibit 4.20 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. CONFIDENTIAL AMENDMENT NO. 2 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR PANCREATIC CANCER STUDY) This Amendment No. 2 to the CLINICAL |
|
| March 16, 2022 |
Exhibit 99.1 For Immediate Release BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motix |
|
| March 16, 2022 |
Exhibit 4.24 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. AMENDMENT NO. 1 TO LICENSE AGREEMENT THIS AMENDMENT NO. 1 (?Amendment?) is entered into effective as of June 18th, 2018 (the ?Amendment Effective Da |
|
| March 16, 2022 |
Exhibit 4.23 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. SECOND AMENDMENT AGREEMENT This Amendment Agreement (?Amendment Agreement?), dated as of October 16, 2018 (the ?Execution Date?), is between the Uni |
|
| March 16, 2022 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the ?Company?) hereby certifies to such officer?s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 16, 2022 |
EX-15.1 13 exhibit15-1.htm EXHIBIT 15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-176419, 333-183976, 333-201326 and 333-208865) and Form F-3 (No. 333-251857 and 333-229021) of BioLineRx Ltd. of our report dated March 15, 2022 relating to the financial statements and |
|
| March 16, 2022 |
Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of BioLineRx Ltd. (the ?Company?) hereby certifies to such officer?s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2 |
|
| March 16, 2022 |
Exhibit 4.19 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR PANCREATIC CANCER STUDY) (as amended) This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT |
|
| March 16, 2022 |
Exhibit 4.22 Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted. CONFIDENTIAL Execution Copy PATENT & KNOW-HOW LICENSE AGREEMENT THIS AGREEMENT dated September 19, 2017 is between the following Parties: (1) KODE B |
|
| March 16, 2022 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Mali Zeevi, certify that: 1. I have reviewed this annual report on Form 20-F of BioLineRx Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| March 3, 2022 |
Exhibit 1 For Immediate Release BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization - Results demonstrate highly significant cost benefits of using Motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in all multiple myeloma patients undergoing autologous stem cell transplantation - - Results reinforce and enhance the economic benefit seen in earlier evaluation of Motixafortide in combination with G-CSF, versus G-CSF alone, reported in Oct 2021 - Tel Aviv, Israel, March 3, 2022 ? BioLineRx Ltd. |
|
| March 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by check |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* BioLineRx Ltd. (Name of Issuer) Ordinary Shares, NIS 0.10 par value per share** (Title of Class of Securities) 00971M205 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 24, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by chec |
|
| January 24, 2022 |
EX-99 2 exhibit1.htm PRESS RELEASE Exhibit 1 For Immediate Release BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors - Initial results anticipated in the first half of 2022 - Tel Aviv, Israel, January 24, 2022 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical Compa |
|
| January 18, 2022 |
EX-99 2 exhibit1.htm PRESS RELEASE Exhibit 1 For Immediate Release BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients - NDA submission on track for H1 2022 - Tel Aviv, Israel, January 18, 2022 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today a |
|
| January 18, 2022 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2227069.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 18, 2022 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executi |
|
| December 17, 2021 |
EX-99 2 exhibit1.htm BIOLINERX PROVIDES HIGHLIGHTS FROM ORAL PRESENTATION DELIVERED AT THE 63RD AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING & EXPOSITION Exhibit 1 For Immediate Release BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition - Presentation highlighted successful GENESIS Phase 3 pivotal trial |
|
| December 17, 2021 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2126972.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive |
|
| December 15, 2021 |
SECURITIES AND EXCHANGE COMMISSION 6-K 1 zk2126959.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive |
|
| December 15, 2021 |
EX-99 2 exhibit1.htm PRESS RELEASE Exhibit 1 For Immediate Release BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) - SAB will provide insight and guidance on the Company’s immuno-oncology activities and is comprised of recognized leaders in the fields of cancer immunology, intra-tumoral injections and clinical development - Tel Aviv, Israel, December 15, 2021 – Bio |
|
| December 3, 2021 |
6-K 1 zk2126922.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant’s name into English) 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive |
|
| November 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant?s name into English) 2 HaMa?ayan Street Modi?in 7177871, Israel (Address of Principal Executive Offices) Indicate by che |
|
| November 18, 2021 |
Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2021 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2021 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-2 Condensed consolidated interim statements of comprehensive loss F-3 Condensed consolidated |
|
| November 18, 2021 |
OPERATING AND FINANCIAL REVIEW EX-99 4 exhibit3.htm OPERATING AND FINANCIAL REVIEW Exhibit 3 OPERATING AND FINANCIAL REVIEW You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on February 23, 2021, or the Annual Report. Forward Looking Sta |
|
| November 18, 2021 |
EX-99 2 exhibit1.htm PRESS RELEASE Exhibit 1 For Immediate Release BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF - - Pre-NDA meeting with FDA set for mid-December; NDA submission planned for |
|
| November 4, 2021 |
Exhibit 1 For Immediate Release BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition - Oral presentation highlights successful GENESIS Phase 3 pivotal trial of Motixafortide plus G-CSF for stem cell mobilization in multiple myeloma patients - - Presentations include data showing the addition of Motixafortide to G-CSF rapidly mobilizes large numbers of specific stem cells, which may contribute to shorter engraftment time when infused in high numbers - Tel Aviv, Israel, November 4, 2021 – BioLineRx Ltd. |
